1VKTX Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More details

1VKTX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 69.62% per year

Risk Analysis

Earnings are forecast to decline by an average of 10% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Viking Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Viking Therapeutics
Historical stock prices
Current Share Price	US$25.12
52 Week High	US$25.35
52 Week Low	US$23.19
Beta	0.75
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.81%

Recent updates

Shareholder Returns

	1VKTX	IT Biotechs	IT Market
7D	-0.7%	1.3%	2.3%
1Y	n/a	0.5%	15.7%

Return vs Industry: Insufficient data to determine how 1VKTX performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1VKTX performed against the Italian Market.

Price Volatility

Is 1VKTX's price volatile compared to industry and market?
1VKTX volatility
1VKTX Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1VKTX's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1VKTX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	46	Brian Lian	www.vikingtherapeutics.com

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

Viking Therapeutics, Inc. Fundamentals Summary

How do Viking Therapeutics's earnings and revenue compare to its market cap?
1VKTX fundamental statistics
Market cap	€2.86b
Earnings (TTM)	-€115.01m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-24.9x

P/E Ratio

Is 1VKTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1VKTX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$128.24m
Earnings	-US$128.24m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.14
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 1VKTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 21:12
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viking Therapeutics, Inc. is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Luchini	BMO Capital Markets Equity Research
Mayank Mamtani	B. Riley Securities, Inc.
William Frohnhoefer	BTIG

Viking Therapeutics BIT:1VKTX Stock Report